Bcl-2 and Fas, Molecules Which Influence Apoptosis. A Possible Role in Systemic Lupus Erythematosus?

References

• Wyllie AH. Apoptosis: cell death in tissue regulation. J Pathol 1987; 153: 313–6
   PubMed Web of Science ®Google Scholar
• Raff MC. Social controls on cell survival and cell death. Nature 1992; 356: 397–400
   PubMed Web of Science ®Google Scholar
• Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984; 142: 67–77
   PubMed Web of Science ®Google Scholar
• Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132: 38–42
   PubMed Web of Science ®Google Scholar
• Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987; 139: 3199–206
   PubMed Web of Science ®Google Scholar
• Martin SJ, Lennon SV, Bonham AM, Cotter TG. Induction of apoptosis (programmed cell death) in human leukaemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 1990; 145: 1859–67
   PubMed Web of Science ®Google Scholar
• Duke RC, Cohen JJ. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. J Lymphoidne Res 1986; 5: 289–99
   PubMed Web of Science ®Google Scholar
• Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JT. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337: 181–4
   PubMed Web of Science ®Google Scholar
• Schmid D, Tite J, Ruddle N DNA. fragmentation: manifestation of target cell destruction mediated by cytotoxic T-cell lines, lymphotoxin-secreting helper T-cell clones, and cell-free lymphotoxin-containing supernatant. Proc Natl Acad Sci USA 1986; 83: 1881–5
   PubMed Web of Science ®Google Scholar
• Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptosis and necrotic forms of cell lysis. J Immunol 1988; 141: 2629–34
   PubMed Web of Science ®Google Scholar
• Liu Y-J, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan ICM. Mechanism of antigen-driven selection in germinal centres. Nature 1989; 342: 929–31
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Tsokos GC, Mann DL, Eleftheriades EG, Harris CC, Marg GE. Increased proto-oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1986; 29: 755–60
   PubMed Web of Science ®Google Scholar
• Wangel AG. Serological tests in the assessment of disease activity in systemic lupus erythematosus. Scand J Rheum 1986; 15: 353–5
   PubMed Web of Science ®Google Scholar
• Izui S, McConahey PJ, Dixon I J. Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol 1978; 121: 2213–19
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M, Francisco P, Quisorio, Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4 + cells to support autoantibody synthesis. Arthritis Rheum 1990; 33: 1216–25
   PubMedGoogle Scholar
• Ishida H, Kumagai S, Umehara H. Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 1987; 139: 1070–4
   PubMed Web of Science ®Google Scholar
• Sakane T, Steinberg D, Green I. Studies of immune functions of patients with systemic lupus erythematosus. Arthritis Rheum 1978; 21: 657–64
   PubMed Web of Science ®Google Scholar
• Tsokas GC, Magrath IT, Balow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 1983; 131: 1797–801
   PubMed Web of Science ®Google Scholar
• Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 1987; 80: 1512–5
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular cancer. Oncogene 1987; 2: 3–7
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–6
   PubMed Web of Science ®Google Scholar
• Alnemri ES, Robertson NM, Fernandes TF, Croce CM. Overexpressed full-length human Bcl2 extends the survival of baculovirus-infected Sf9 insect cells. Proc Natl Acad Sci USA 1992; 89: 7295–9
   PubMed Web of Science ®Google Scholar
• Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361: 365–9
   PubMed Web of Science ®Google Scholar
• Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Greaves MF. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992; 40: 1819–25
   PubMed Web of Science ®Google Scholar
• Tanaka S, Saito K, Reed JC. Structure-function analysis of the bcl-2 oncoprotein. J Biol Chem 1993; 268: 10920–6
   PubMed Web of Science ®Google Scholar
• White E. Death-defying acts: a meeting review on apoptosis. Genes and Development. 1993; 7: 2277–84
   Google Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–2
   PubMed Web of Science ®Google Scholar
• Vaux DL, Weissman IL, Kim SK. Prevention of programmed cell death in Caenorhabditis elegans. Science 1992; 258: 1955–7
   PubMed Web of Science ®Google Scholar
• Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992; 356: 494–9
   PubMed Web of Science ®Google Scholar
• Yuan JY, Horvitz HR. The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 1990; 138: 33–41
   PubMed Web of Science ®Google Scholar
• Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241–51
   PubMed Web of Science ®Google Scholar
• Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair. Cell 1993; 75: 229–40
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimer-izes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993; 74: 609–19
   PubMed Web of Science ®Google Scholar
• Boise LH, Gonzalez-Garcia M, Postema CE. Bcl-x. a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608
   PubMed Web of Science ®Google Scholar
• Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88: 6961–5
   PubMed Web of Science ®Google Scholar
• Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer S. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879–88
   PubMed Web of Science ®Google Scholar
• Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol 1990; 137: 225–32
   PubMed Web of Science ®Google Scholar
• Reed JC, Miyashita T, Cuddy M, Cho D. Regulation of p26-Bcl-2 protein levels in human peripheral blood lymphocytes. Lab Invest 1992; 67: 443–9
   PubMed Web of Science ®Google Scholar
• Cuende E, Ales-Martinez JE, Ding L, Gonzalez-Garcia M, Martinez-A C, Nunez G. Programmed cell death by bcl-2 dependent and independent mechanisms in B lymphoma cells. EMBOJ 1993; 12: 1555–60
   PubMed Web of Science ®Google Scholar
• Basten A, Brink R, Peake P. Self-tolerance in the B-cell repertoire. Immunol Rev 1991; 122: 5–19
   PubMed Web of Science ®Google Scholar
• Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747–56
   PubMed Web of Science ®Google Scholar
• Trauth BC, Klas C, Peters AMJ. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 254: 301–4
   Google Scholar
• Clark EA. CD40: a cytokine receptor in search of a ligand. Tissue Antigens 1990; 35: 33–6
   Google Scholar
• Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629–34
   PubMed Web of Science ®Google Scholar
• Miyawaki T, Uehara T, Nibu R. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149: 3753–8
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan CI, Itoh N. The cDNA structure, expression, and chromsomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274–9
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–78
   PubMed Web of Science ®Google Scholar
• Rouvier E, Luciani M-F, Goldstein P. Fas involvement in Ca2+ -independent T cell-mediated cytotoxicity. J Exp Med 1993; 177: 195–200
   PubMed Web of Science ®Google Scholar
• Dhein J, Daniel PT, Trauth BC, Oehm A, Mdller P, Kram-Mer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992; 149: 3166–73
   PubMed Web of Science ®Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–9
   PubMed Web of Science ®Google Scholar
• McDonnell JJ, Deane N, Piatt FM. Bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 58: 79–88
   Google Scholar
• Katsuma M, Siegel RM, Louie DC. Differential effects of bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 1992; 89: 11376–80
   PubMed Web of Science ®Google Scholar
• Strasser A, Whittingham S, Vaux DLel AL. Enforced bcl-2 expression in B lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661–5
   PubMed Web of Science ®Google Scholar
• Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune disease and probes for cell biology. Adv Immunol 1989; 44: 93–151
   PubMed Web of Science ®Google Scholar
• Murphy ED, Roths JB. Autoimmunity and lymphoproliferation: induction by mutant gene Ipr and acceleration by a male associated factor in strain BXSB. Control of autoimmune diseases, NR Rose, PE Bigazzi, NL. Warner. Elsevier, North Holland, New York 1979; 207–20
   Google Scholar
• Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Ann Rev Immunol 1991; 9: 243–69
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yoshikai Y, Asano T, Himeno K, Iwasaki A, Nomoto K. Defect in negative selection in lpr donor-derived T cells differentiating in non-lpr host thymus. J Exp Med 1991; 173: 127–36
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–7
   PubMed Web of Science ®Google Scholar
• Wu J, Zhou T, Mountz JD. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 1993; 178: 461–8
   PubMed Web of Science ®Google Scholar
• Itoh N, Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932–7
   PubMed Web of Science ®Google Scholar
• Itoh N, Yonehara S, Ishii A. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–43
   PubMed Web of Science ®Google Scholar
• Mountz JD, Wu J, Zhang J, He J, Zhou T. Correction of autoimmune disease in Fas transgenic MRL-lpr/lpr mice (abstract). Arthritis Rheum 1993; 36: S52
   Google Scholar
• Graninger WB. Transcriptional overexpression of the proto-oncogene bcl-2 in patients with systemic lupus erythematosus. Wien Klin Wochenschr 1992; 104: 205–7
   PubMed Web of Science ®Google Scholar
• Rose LM, Latchman DS, Isenberg DA. Bcl-2 expression is unaltered in unfractionated peripheral blood mononuclear cells in patients with systemic lupus erythematosus. 1993, Submitted
   Google Scholar
• Kumagai S, Yanagida H, Tsujimoto Y. Increased expression of bcl-2 protein in peripheral B cells of patients with systemic lupus erythematosus (SLE) (abstract). Arthritis Rheum 1993; 36: S76
   Google Scholar
• Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621–7
   PubMed Web of Science ®Google Scholar
• Evan GI, Wyllie A, Gilbert CS. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119–28
   PubMed Web of Science ®Google Scholar
• Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552–4
   PubMed Web of Science ®Google Scholar
• Oehm A, Behrmann I, Falk W. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J Biol Chem 1992; 267: 10709–15
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2 the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214–8
   PubMed Web of Science ®Google Scholar